HSBC Securities upgraded Labcorp Holdings Inc. from Hold to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
| 2/26/2024 | $260.00 | Outperform | Leerink Partners |
| 2/9/2024 | $240.00 | In-line | Evercore ISI |
| 1/3/2024 | $222.00 | Equal Weight | Barclays |
| 9/6/2023 | $210.00 | Hold | HSBC Securities |
| 12/12/2022 | $275.00 → $250.00 | Buy → Neutral | Citigroup |
10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- Reuters
-Reuters
Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Holdings (NYSE:LH) with a In-Line and raises the price target from $210 to $215.
Collaboration to leverage Praia Health's technology and Labcorp's comprehensive testing capabilities to streamline and personalize patient experience Praia Health, the consumer experience orchestration platform for health systems, is pleased to announce it has secured a strategic investment from the Labcorp Venture Fund and will collaborate with Labcorp, a global leader of innovative and comprehensive laboratory services, to streamline and personalize the patient experience for lab orders and testing within select health systems. "Our collaboration with Labcorp represents a significant step forward in delivering personalized and seamless healthcare experiences," said Justin Dearborn, CEO
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesBURLINGTON, N.C., Oct. 24, 2024 /PRNewswire/ -- Labcorp
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
HSBC Securities upgraded Labcorp Holdings Inc. from Hold to Buy
Piper Sandler initiated coverage of Labcorp Holdings Inc. with a rating of Neutral and set a new price target of $235.00
Argus upgraded Laboratory Corp from Hold to Buy and set a new price target of $250.00
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesBURLINGTON, N.C., Oct. 24, 2024 /PRNewswire/ -- Labcorp
BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident de
BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also